In a report released today, Gus Richard from Northland Securities maintained a Buy rating on Enovix, with a price target of $25.00. The company’s shares closed yesterday at $13.40. Take advantage of ...

In addition to Canaccord Genuity, Enovix also received a Buy from Northland Securities’s Gus Richard in a report issued today. However, on the same day, TD Cowen assigned a Hold rating to Enovix ...

Hims & Hers Health ($HIMS) is scheduled to announce its results for the second quarter of 2025 after the market closes on Monday, August 4. HIMS ...

Axon Enterprise, Inc. (NASDAQ: AXON) ranks among the best growth stocks to buy for the next 10 years. Ahead of the company’s ...

Just because a stock is a Dividend Champion doesn't mean it's an overall winner. However, some members of the group could be attractive to investors. Here are three Dividend Champion stocks I'm ...

CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced ...

Key growth updates included the closing of a 10% interest acquisition in the Matterhorn Express pipeline, upsizing the Traverse Pipeline project, and sanctioning the $900 million Clear Fork project in ...

Regeneron reports strong Q2 2025 growth with Dupixent sales up 21% and EYLEA HD hitting record highs. Explore key earnings insights and pipeline updates.

Cenovus is now forecasting its 2025 upstream production will be between 805,000 bpd of oil equivalent and 825,000 bpd, compared with 805,000 bpd–845,000 projected previously, because of the temporary ...

In its first commercial quarter for ATTR-cardiomyopathy, Alnylam’s Amvuttra reached roughly 1,400 patients and made more than ...

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, ...

Apple has reported record revenues and done so with success in three key areas, none of which required Apple Intelligence, which analysts insisted the company needed to concentrate on. Here's how the ...